Breast cancer
Conditions
Interventions
Cyclophosphamide:600mg/m2 day1 Albumin-bound paclitaxel:150mg/m2-260mg/m2 day1 every 3 weeks
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1Histological confirmed primary breast cancer 2Reccurent,metastatic breast cancer 3No prior chemotherapy for metastasis, the recurrent breast cancer 4The case that passes after treatment of the adjuvant chemotherapy more than 24 weeks 5HER2 negative. 6An age of 20 years to 75 years 7ECOG Performance Status is 0 or 1 8Patient with measurable disease 9Required baseline laboratory data 10Expected survival time more than 60 days 11Written informed consent
Exclusion criteria
Exclusion criteria: 1allergy of the medication 2Serious complications 3Previous or current history of malignant neoplasm 4Clinically significant heart disease 5Peripheral neuropathy grade2 or greater 6Active infection 7Symptomatic brain metastasis 8Uncontrollable pleural effusion or ascites requiring 9During administraton of pentostatin 10With mental disorder which become problem on clinical practice 11Current pregnancy or lacation,or possibility of pregnancy 12Cases who physician judged improper to entry this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determinate maximum tolerated dose and recommended dose | — |
Countries
Japan
Outcome results
None listed